Abstract
Vaccines are one of mankind’s greatest medical advances, and their use has drastically reduced and in some cases eliminated (e.g., smallpox) disease and death caused by infectious agents. Traditional vaccine modalities including live-attenuated pathogen vaccines, wholly inactivated pathogen vaccines, and protein-based pathogen subunit vaccines have successfully been used to create efficacious vaccines against measles, mumps, rubella, polio, and yellow fever. These traditional vaccine modalities, however, take many months to years to develop and have thus proven less effective for use in creating vaccines to emerging or reemerging infectious diseases (EIDs) including influenza, Human immunodeficiency virus (HIV), dengue virus (DENV), chikungunya virus (CHIKV), West Nile virus (WNV), Middle East respiratory syndrome (MERS), and the severe acute respiratory syndrome coronaviruses 1 and 2 (SARS-CoV and SARS-CoV-2). As factors such as climate change and increased globalization continue to increase the pace of EID development, newer vaccine modalities are required to develop vaccines that can prevent or attenuate EID outbreaks throughout the world. One such modality, DNA vaccines, has been studied for over 30 years and has numerous qualities that make them ideal for meeting the challenge of EIDs including; (1) DNA vaccine candidates can be designed within hours of publishing of a pathogens genetic sequence; (2) they can be manufactured cheaply and rapidly in large quantities; (3) they are thermostable and have reduced requirement for a cold-chain during distribution, and (4) they have a remarkable safety record in the clinic. Optimizations made in plasmid design as well as in DNA vaccine delivery have greatly improved the immunogenicity of these vaccines. Here we describe the process of making a DNA vaccine to an EID pathogen and describe methods used for assessing the immunogenicity and protective efficacy of DNA vaccines in small animal models.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Marshall HS, Plotkin S (2019) The changing epidemiology of mumps in a high vaccination era. Lancet Infect Dis 19(2):118–119. https://doi.org/10.1016/S1473-3099(18)30541-3
Koff WC, Schenkelberg T (2020) The future of vaccine development. Vaccines 38(28):4485–4486. https://doi.org/10.1016/j.vaccine.2019.07.101
Koff WC, Gust ID, Plotkin SA (2014) Toward a human vaccines project. Nat Immunol 15(7):589–592. https://doi.org/10.1038/ni.2871
Wong G, Qiu X (2018) Funding vaccines for emerging infectious diseases. Hum Vaccin Immunother 14(7):1760–1762. https://doi.org/10.1080/21645515.2017.1412024
Henrickson SE (2020) Learning from our immunological history: what can SARS-CoV teach us about SARS-CoV-2? Sci Immunol 5(46):eabb8618. https://doi.org/10.1126/sciimmunol.abb8618
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382(10):929–936. https://doi.org/10.1056/NEJMoa2001191
de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14(8):523–534. https://doi.org/10.1038/nrmicro.2016.81
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (2020) The proximal origin of SARS-CoV-2. Nat Med 26(4):450–452. https://doi.org/10.1038/s41591-020-0820-9
Plotkin SA (2020) Updates on immunologic correlates of vaccine-induced protection. Vaccines 38(9):2250–2257. https://doi.org/10.1016/j.vaccine.2019.10.046
Koff WC, Williams MA (2020) Covid-19 and immunity in aging populations - a new research agenda. N Engl J Med 383(9):804–805. https://doi.org/10.1056/NEJMp2006761
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513. https://doi.org/10.1016/S0140-6736(20)30211-7
Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S et al (2020) Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. Science 368(6498):1481–1486. https://doi.org/10.1126/science.abb8001
Bernasconi V, Kristiansen PA, Whelan M, Roman RG, Bettis A, Yimer SA et al (2020) Developing vaccines against epidemic-prone emerging infectious diseases. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 63(1):65–73. https://doi.org/10.1007/s00103-019-03061-2
Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H et al (2020) Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52(6):971–7.e3. https://doi.org/10.1016/j.immuni.2020.04.023
Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K et al (2019) Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis 19(9):1013–1022. https://doi.org/10.1016/S1473-3099(19)30266-X
Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI et al (2017) Safety and immunogenicity of an anti-zika virus DNA vaccine - preliminary report. N Engl J Med. https://doi.org/10.1056/NEJMoa1708120
Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J et al (2020) Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun 11(1):2601. https://doi.org/10.1038/s41467-020-16505-0
Perkel JM (2016) NIH dengue vaccine leaps into phase 3 studies. Nat Biotechnol 34(5):449. https://doi.org/10.1038/nbt0516-449
Erasmus JH, Auguste AJ, Kaelber JT, Luo H, Rossi SL, Fenton K et al (2017) A chikungunya fever vaccine utilizing an insect-specific virus platform. Nat Med 23(2):192–199. https://doi.org/10.1038/nm.4253
Kongsgaard M, Bassi MR, Rasmussen M, Skjødt K, Thybo S, Gabriel M et al (2017) Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination. Sci Rep 7(1):662. https://doi.org/10.1038/s41598-017-00798-1
McMichael AJ, Koff WC (2014) Vaccines that stimulate T cell immunity to HIV-1: the next step. Nat Immunol 15(4):319–322. https://doi.org/10.1038/ni.2844
Maslow JN (2017) Vaccine development for emerging virulent infectious diseases. Vaccines 35(41):5437–5443. https://doi.org/10.1016/j.vaccine.2017.02.015
Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB (2013) Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 4:354. https://doi.org/10.3389/fimmu.2013.00354
Hobernik D, Bros M (2018) DNA vaccines-how far from clinical use? Int J Mol Sci 19(11):3605. https://doi.org/10.3390/ijms19113605
Gary EN, Weiner DB (2020) DNA vaccines: prime time is now. Curr Opin Immunol 65:21–27. https://doi.org/10.1016/j.coi.2020.01.006
Saade F, Petrovsky N (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 11(2):189–209. https://doi.org/10.1586/erv.11.188
Xu Z, Wise MC, Choi H, Perales-Puchalt A, Patel A, Tello-Ruiz E et al (2018) Synthetic DNA delivery by electroporation promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-Ig. EBioMedicine 35:97–105. https://doi.org/10.1016/j.ebiom.2018.08.027
Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL et al (2017) Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A 114(35):E7348–E7E57. https://doi.org/10.1073/pnas.1707304114
Rappuoli R, De Gregorio E, Costantino P (2019) On the mechanisms of conjugate vaccines. Proc Natl Acad Sci U S A 116(1):14–16. https://doi.org/10.1073/pnas.1819612116
Kotliarov Y, Sparks R, Martins AJ, Mule MP, Lu Y, Goswami M et al (2020) Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus. Nat Med 26(4):618–629. https://doi.org/10.1038/s41591-020-0769-8
Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS et al (2018) Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 391(10120):552–562. https://doi.org/10.1016/S0140-6736(17)33105-7
Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Cheung J et al (2020) Immune therapy targeting E6/E7 oncogenes of human papillomavirus type 6 (HPV-6) reduces or eliminates the need for surgical intervention in the treatment of HPV-6 associated recurrent respiratory papillomatosis. Vaccines (Basel) 8(1):56. https://doi.org/10.3390/vaccines8010056
Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH et al (2020) DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369(6505):806–811. https://doi.org/10.1126/science.abc6284
Rouphael NG, Morgan C, Li SS, Jensen R, Sanchez B, Karuna S et al (2019) DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. J Clin Invest 129(11):4769–4785. https://doi.org/10.1172/JCI128699
Perales-Puchalt A, Duperret EK, Yang X, Hernandez P, Wojtak K, Zhu X et al (2019) DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity. JCI Insight 4(8):e126086. https://doi.org/10.1172/jci.insight.126086
Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO et al (2015) A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 7(301):301ra132. https://doi.org/10.1126/scitranslmed.aac7462
Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA et al (2011) A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 5(1):e928. https://doi.org/10.1371/journal.pntd.0000928
Wise MC, Xu Z, Tello-Ruiz E, Beck C, Trautz A, Patel A et al (2020) In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. J Clin Invest 130:827. https://doi.org/10.1172/JCI132779
Sampath S, Carrico C, Janes J, Gurumoorthy S, Gibson C, Melcher M et al (2013) Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development. PLoS Pathog 9(6):e1003420. https://doi.org/10.1371/journal.ppat.1003420
Xu Z, Kulp DW (2019) Protein engineering and particulate display of B-cell epitopes to facilitate development of novel vaccines. Curr Opin Immunol 59:49–56. https://doi.org/10.1016/j.coi.2019.03.003
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O et al (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367(6483):1260–1263. https://doi.org/10.1126/science.abb2507
Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP et al (2015) Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21(9):1065–1070. https://doi.org/10.1038/nm.3927
Duan H, Chen X, Boyington JC, Cheng C, Zhang Y, Jafari AJ et al (2018) Glycan masking focuses immune responses to the HIV-1 CD4-binding site and enhances elicitation of VRC01-class precursor antibodies. Immunity 49(2):301–11.e5. https://doi.org/10.1016/j.immuni.2018.07.005
Kulp DW, Steichen JM, Pauthner M, Hu X, Schiffner T, Liguori A et al (2017) Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat Commun 8(1):1655. https://doi.org/10.1038/s41467-017-01549-6
Xu Z, Wise MC, Chokkalingam N, Walker S, Tello-Ruiz E, Elliott STC et al (2020) In vivo assembly of nanoparticles achieved through synergy of structure-based protein engineering and synthetic DNA generates enhanced adaptive immunity. Adv Sci 7(8):1902802. https://doi.org/10.1002/advs.201902802
Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O et al (2015) HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349(6244):156–161. https://doi.org/10.1126/science.aac5894
Gilda JE, Ghosh R, Cheah JX, West TM, Bodine SC, Gomes AV (2015) Western blotting inaccuracies with unverified antibodies: need for a western blotting minimal reporting standard (WBMRS). PLoS One 10(8):e0135392. https://doi.org/10.1371/journal.pone.0135392
Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Harris LW, Bahn S (2011) Proteomic technologies for biomarker studies in psychiatry: advances and needs. Int Rev Neurobiol 101:65–94. https://doi.org/10.1016/B978-0-12-387718-5.00004-3
Alegria-Schaffer A, Lodge A, Vattem K (2009) Performing and optimizing Western blots with an emphasis on chemiluminescent detection. Methods Enzymol 463:573–599. https://doi.org/10.1016/S0076-6879(09)63033-0
Payne S (2017) Methods to study viruses. Viruses 2017:37–52. https://doi.org/10.1016/B978-0-12-803109-4.00004-0
Choi H, Kudchodkar SB, Reuschel EL, Asija K, Borole P, Agarwal S et al (2020) Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge. Hum Vaccin Immunother 16(4):907–918. https://doi.org/10.1080/21645515.2019.1688038
Zankharia US, Kudchodkar S, Khoshnejad M, Perales-Puchalt A, Choi H, Ho M et al (2020) Neutralization of hepatitis B virus by a novel DNA-encoded monoclonal antibody. Hum Vaccin Immunother 16:2156–2164. https://doi.org/10.1080/21645515.2020.1763686
Simonetti FR, Dewar R, Maldarelli F (2015) Diagnosis of human immunodeficiency virus infection. In: Bennett JE, Dolin R, Blaser MJ (eds) Principles and practice of infectious diseases, 8th edn. Elsevier, Philadelphia, PA, pp 1503–25.e7
Choi H, Kudchodkar SB, Reuschel EL, Asija K, Borole P, Ho M et al (2019) Protective immunity by an engineered DNA vaccine for Mayaro virus. PLoS Negl Trop Dis 13(2):e0007042. https://doi.org/10.1371/journal.pntd.0007042
Sia SF, Yan LM, Chin AWH, Fung K, Choy KT, Wong AYL et al (2020) Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583(7818):834–838. https://doi.org/10.1038/s41586-020-2342-5
Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N et al (2015) A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J Virol 89(6):3380–3395. https://doi.org/10.1128/JVI.03473-14
Wang Q, Ma B, Liang Q, Zhu A, Wang H, Fu L et al (2020) Stabilized diverse HIV-1 envelope trimers for vaccine design. Emerg Microbes Infect 9(1):775–786. https://doi.org/10.1080/22221751.2020.1745093
Kudchodkar SB, Choi H, Reuschel EL, Esquivel R, Jin-Ah Kwon J, Jeong M et al (2018) Rapid response to an emerging infectious disease - lessons learned from development of a synthetic DNA vaccine targeting Zika virus. Microbes Infect 20(11–12):676–684. https://doi.org/10.1016/j.micinf.2018.03.001
Kirchdoerfer RN, Wang N, Pallesen J, Wrapp D, Turner HL, Cottrell CA et al (2018) Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep 8(1):15701. https://doi.org/10.1038/s41598-018-34171-7
Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N et al (2013) A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9(9):e1003618. https://doi.org/10.1371/journal.ppat.1003618
Sahin E, Roberts CJ (2012) Size-exclusion chromatography with multi-angle light scattering for elucidating protein aggregation mechanisms. Methods Mol Biol 899:403–423. https://doi.org/10.1007/978-1-61779-921-1_25
Hong P, Koza S, Bouvier ES (2012) Size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. J Liq Chromatogr Relat Technol 35(20):2923–2950. https://doi.org/10.1080/10826076.2012.743724
Lyumkis D (2019) Challenges and opportunities in cryo-EM single-particle analysis. J Biol Chem 294(13):5181–5197. https://doi.org/10.1074/jbc.REV118.005602
Li Y, O’Dell S, Walker LM, Wu X, Guenaga J, Feng Y et al (2011) Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol 85(17):8954–8967. https://doi.org/10.1128/JVI.00754-11
Lee JH, Andrabi R, Su CY, Yasmeen A, Julien JP, Kong L et al (2017) A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure. Immunity 46(4):690–702. https://doi.org/10.1016/j.immuni.2017.03.017
Wu X, Sambor A, Nason MC, Yang ZY, Wu L, Zolla-Pazner S et al (2008) Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. Virology 380(2):285–295. https://doi.org/10.1016/j.virol.2008.07.007
Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP et al (2020) Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med 383:1544. https://doi.org/10.1056/NEJMoa2024671
Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17(7):1055–1065. https://doi.org/10.1128/CVI.00131-10
Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC et al (2020) Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill 25(16):2000421. https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000421
Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L et al (2020) Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell 182(1):73–84.e16. https://doi.org/10.1016/j.cell.2020.05.025
Lebourgeois S, Fraisse A, Hennechart-Collette C, Guillier L, Perelle S, Martin-Latil S (2018) Development of a real-time cell analysis (RTCA) method as a fast and accurate method for detecting infectious particles of the adapted strain of hepatitis A virus. Front Cell Infect Microbiol 8:335. https://doi.org/10.3389/fcimb.2018.00335
Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM et al (2014) Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods 409:131–146. https://doi.org/10.1016/j.jim.2013.11.022
Bilska M, Tang H, Montefiori DC (2017) Short communication: potential risk of replication-competent virus in HIV-1 Env-pseudotyped virus preparations. AIDS Res Hum Retrovir 33(4):368–372. https://doi.org/10.1089/AID.2016.0142
Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M Jr, Carville A et al (2012) ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 8(8):e1002890. https://doi.org/10.1371/journal.ppat.1002890
Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K et al (2016) Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun 7:10844. https://doi.org/10.1038/ncomms10844
Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y et al (2007) Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol 44(12):3122–3131. https://doi.org/10.1016/j.molimm.2007.02.005
Naso MF, Tam SH, Scallon BJ, Raju TS (2010) Engineering host cell lines to reduce terminal sialylation of secreted antibodies. MAbs 2(5):519–527. https://doi.org/10.4161/mabs.2.5.13078
Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):176–180. https://doi.org/10.1038/6179
Ebihara H, Takada A, Kobasa D, Jones S, Neumann G, Theriault S et al (2006) Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2(7):e73. https://doi.org/10.1371/journal.ppat.0020073
Wong G, Qiu XG (2018) Type I interferon receptor knockout mice as models for infection of highly pathogenic viruses with outbreak potential. Zool Res 39(1):3–14. https://doi.org/10.24272/j.issn.2095-8137.2017.052
Cugola FR, Fernandes IR, Russo FB, Freitas BC, Dias JL, Guimaraes KP et al (2016) The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534(7606):267–271. https://doi.org/10.1038/nature18296
Sun J, Zhuang Z, Zheng J, Li K, Wong RL, Liu D et al (2020) Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182(3):734–43.e5. https://doi.org/10.1016/j.cell.2020.06.010
Bao L, Deng W, Huang B, Gao H, Liu J, Ren L et al (2020) The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583(7818):830–833. https://doi.org/10.1038/s41586-020-2312-y
Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J et al (2020) Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369(6505):818–823. https://doi.org/10.1126/science.abc5343
Guebre-Xabier M, Patel N, Tian J-H, Zhou B, Maciejewski S, Lam K et al (2020) NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. BioRxiv:256578
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN et al (2020) An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 383:1920. https://doi.org/10.1056/NEJMoa2022483
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586:589. https://doi.org/10.1038/s41586-020-2639-4
Maciejewski S, Ruckwardt TJ, Morabito KM, Foreman BM, Burgomaster KE, Gordon DN et al (2020) Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Sci Transl Med 12(547):eaaw9066. https://doi.org/10.1126/scitranslmed.aaw9066
Manners C, Larios Bautista E, Sidoti H, Lopez OJ (2020) Protective adaptive immunity against severe acute respiratory syndrome coronaviruses 2 (SARS-CoV-2) and implications for vaccines. Cureus 12(6):e8399. https://doi.org/10.7759/cureus.8399
van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR et al (2020) ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. BioRxiv:093195
Acknowledgments
K.M. is supported by Wistar-Discovery fund and W.W. Smith Charitable Trust grant #H1905. He has a patent application for DNA vaccine development and delivery of DNA-encoded monoclonal antibodies. M.A-M is supported by NIH grants (R01 DK123733, R01 AG062383, R01 NS117458, R21 AI143385, R21 AI129636, and R21 NS106970), The Foundation for AIDS Research (amfAR) impact grant #109840-65-RGRL, and W.W. Smith Charitable Trust grant #A1901. The other authors declare no competing financial interests.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Xu, Z. et al. (2022). Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 2410. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1884-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1884-4_11
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1883-7
Online ISBN: 978-1-0716-1884-4
eBook Packages: Springer Protocols